Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Concanavalin A inhibits tissue factor coagulant activity.
F A Pitlick
F A Pitlick
Published January 1, 1975
Citation Information: J Clin Invest. 1975;55(1):175-179. https://doi.org/10.1172/JCI107908.
View: Text | PDF
Research Article

Concanavalin A inhibits tissue factor coagulant activity.

  • Text
  • PDF
Abstract

Concanavalin A (con A) is a potent inhibitor of coagulant activity of native tissue factor. Coagulant activity is recovered by addition of alpha-methyl-D-glucoside to inhibited tissue factor. Inclusion of alpha-methyl-D-glucose during incubation of con A with tissue factor preserves coagulant activity. These data suggest that con A interacts reversibly with a carbohydrate residue in such a way as to inhibit coagulant activity of the molecule. Purified tissue factor apoprotein has been recombined with mixed brain phospholipids or purified phospholipids (phosphatidyl ethanolamine or a mixture of phosphatidyl choline with phosphatidyl serine). These preparations were also completely but reversibly inhibited by con A. Thus, purified tissue factor apoprotein appears to donate the affected carbohydrate residue.

Authors

F A Pitlick

×

Loading citation information...
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts